Immune response and safety of AE 37 plus HER2/Neu GP2 vaccine in patients with breast and ovarian cancer.

Trial Profile

Immune response and safety of AE 37 plus HER2/Neu GP2 vaccine in patients with breast and ovarian cancer.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2014

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top